Her basic science research interest is focused on regulatory T cells, their involvement in disease pathogenesis and prevention of autoimmune disorders including graft versus Host Disease. Based on the technologies arising from the laboratory investigations of Simrit Parmar, M.D., The University of Texas at MD Anderson Cancer Center and Golden Meditech Holdings Limited, a Hong Kong-based integrated healthcare enterprise have created Cellenkos, Inc., a start-up enterprise focused on umbilical cord blood derived T-regulatory ("T-reg") cellular therapies. Dr Simrit Parmar, serves as the Founder Director and Chief Medical Officer of Cellenkos. Please click here to review institutional conflict of interest management plan.